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Introduction
The proto-oncogenes N-ras, H-ras and K-ras encode 21 kDa GTP binding proteins of central importance in signal transduction in all cells. 1 In hemopoiesis, the importance of Ras is indicated by its involvement in the signaling pathways activated by the majority of hemopoietic growth factors. 2, 3 Ras functions as a molecular switch in signal transduction and is active when in the GTP-bound state and inactive when the bound GTP is hydrolyzed to GDP. Oncogenic Ras mutations generally result in severe impairment of Ras GTPase activity and thus stimulate cell growth or differentiation autonomously.
Oncogenic Ras stimulates proliferation in normal human long-term bone marrow cultures and also in a number of hemopoietic cell lines. [4] [5] [6] [7] However, it is also known to promote differentiation in a number of other cell lines. [8] [9] [10] Recent data indicate that in hematopoietic cells Ras may promote either proliferation or differentiation depending on the cell type and the state of maturation. 9 Expression of oncogenic Ras is detected in around 30% of cases of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) 11 and juvenile chronic myeloid leukemia (CML). 12 The majority of mutations involve a
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Received 13 January 1998; accepted 27 March 1998 point mutation at codon 12 or 13 within exon 1 of the N-ras gene. 13 N-ras mutations have also been found in neuroblastoma, melanoma and multiple myeloma. 14 The use of antisense nucleic acids and ribozymes to suppress aberrant gene expression is well documented. [15] [16] [17] Hammerhead ribozymes are particularly attractive for this purpose because only a small target region within the substrate molecule is required for cleavage. Ribozymes can be directed against virtually any target sequences by flanking the catalytic core domain with complementary sequences to the target region. 18, 19 Substrates containing an NUH triplet (N can be any base; H can be A, C or U) in the presence of Mg 2+ can be cleaved by transesterification leading to a cyclic 2Ј,3Ј-phosphate on H.
Previously, we have shown that a synthetic ribozyme (MRE763C) targeted against a mutant N-ras gene containing a G to C transversion at position 763 (codon 13) displayed specific activity in vitro and in cell lines. 20 Exogenous delivery of MRE763C to HeLa cells expressing an N 13 -ras/luciferase fusion transcript led to almost 60% reduction in luciferase activity. The catalytic activity of MRE763C was specific, since no reduction in luciferase activity was observed when MRE763C was delivered to HeLa cells expressing a luciferase fusion transcript containing wild-type N-ras sequences. However, for an effective therapeutic application of ribozymes intracellular expression is required to allow colocalization of the ribozyme with the chosen substrate. 21 To date, we have engineered retroviral vectors to express ribozyme MRE763C and derivatives thereof. We show here, that the in vitro catalytic efficiency of ribozyme MRE763C within the retroviral backbone was not significantly altered compared with that embedded in only 86 nucleotide flanking sequences. The transformed phenotype of a human hematopoietic cell line (TF-1) expressing oncogenic N 13 -ras was reverted after retrovirus-mediated expression of the active but not the inactive form of MRE763C. Reversion of the transformed phenotype correlated with a decrease in the amounts of N 13 -ras transcripts in TF-1 cells.
Results

Retroviral vectors
The retroviral vector pBabe-puro 22 was selected to express ribozyme MRE763C in eukaryotic cells. MRE763C was cloned within the polylinker region of pBabe-puro under the transcriptional control of the viral LTR to generate pBabe-REC ( Figure 1 ). In this construct, the ribozyme is expressed within a 2658 nucleotides long transcript starting at the 5Ј-LTR and ending at the polyadenylation site within the 3Ј-LTR. Similarly, a nonsense ribozyme containing an active catalytic site, but no homology to N-ras sequences, was generated to serve as control for specific cleaveage (pBabe-NRE). A third retroviral vector (pBabe-IRE) contained an inactive form of MRE763C (single point mutation at the catalytic site) and was used to estimate the degree of antisense suppression of N-Ras function in transduced cells.
Catalytic activity of pBabe-REC transcripts in vitro
Since the sequences flanking the catalytic site determines specificity and efficiency of ribozyme cleaveage, we asked whether the flanking sequences in pBabe-REC would influence the catalytic activity of ribozyme MRE763C. For this, plasmid pBabe-REC was digested with SacI and the resulting 2590 bp DNA fragment, containing most of the retroviral genome including MRE763C, was cloned into pBluescript KS to generate pBlue-BabeREC. The SacI recognition site at the 5Ј-LTR in pBabe-REC is located 31 bp upstream of the viral transcription initiation site. Thus, T7-mediated transcription of NotI-linearized pBlue-BabeREC generates a RNA transcript of 2618 nucleotides (Figure 2a ). This size is almost identical to that expected from transcription of pBabe-REC in eukaryotic cells (2658 nucleotides). Similarly, a DNA fragment containing the sequence of MRE763C was cloned in pBluescript to generate pBlue-REC. In vitro transcription of pBlue-REC results in an 86 nucleotide long catalytic RNA where the 32 nucleotides long ribozyme transcript is flanked by 54 nonpairing nucleotides (Figure 2a ). The in vitro catalytic efficiencies of pBlue-BabeREC and pBlue-REC transcripts were compared against a 32 P-labeled N 13 -ras RNA substrate ( Table 1) . Incubation of increasing amounts of pBlue-REC transcripts with 2 nm substrate under 'single-turnover' conditions resulted in the expected cleavage products of 534 and 315 bases which were clearly visible at a ribozyme concentration of 50 nm ( Figure 2b ). The 2618 nucleotides long pBlueBabeREC trancripts also cleaved the N 13 -ras substrate (Figure 2b ), but at slightly lower rates than the pBlue-REC transcripts (73% of that observed with pBlue-REC transcripts; Table 1 ), suggesting that the cleavage activity of MRE763C is independent of the length and composition of non-base pairing sequences flanking the ribozyme. The cleavage efficiency (k react /K m ) of the pBlueBabeREC transcripts was similar (70%) to that of pBlue-REC transcripts (2590 [s
indicating that in this system the overall catalytic efficiency of pBlue-BabeREC transcripts on larger RNA substrates is dictated by the ribozyme moiety itself. 23 Catalytic activity of pBabe-REC transcripts in HeLa cells expressing a N 13 -ras/luciferase fusion transcript The catalytic activity of pBabe-REC was evaluated in cell lines after retrovirus-mediated transfer of MRE763C in the HeLa cell clone C3 which expresses an N 13 -ras/luciferase fusion transcript. 20 In this setting, ribozyme-mediated cleavage of N
13
-ras transcripts led to a reduction in luciferase activity. 20 As a control, HeLa cells were transduced with the retroviral vector alone (pBabe-puro), or with a pBabe vector containing either a nonsense ribozyme (pBabe-NRE) or an inactive form of MRE763C (pBabe-IRE). After transduction, puromycinresistant clones were isolated, expanded and tested for luciferase activity. Figure 3a shows the mean luciferase activity of six independent clones for each construct. Transduction of HeLa with the control retroviral constructs always resulted in a low but detectable reduction in luciferase activity when compared with that of untransduced cells (results not shown). To account for this unspecific reduction in luciferase activity, the luciferase activity of HeLa cell clones transduced with pBabe- 
(a) HeLa cells were infected with either the retroviral vector alone (pBabe-puro, lane 2), or with retroviral vectors containing a nonsense ribozyme (pBabe-NRE, lane 1), an inactive ribozyme (pBabe-IRE, lane 3) or the active ribozyme MRE763C (pBabe-REC, lane 4). The data are representative of the mean luciferase activity of six independent experiments. The standard deviation for each set of data is shown. (b) Expression of ribozymes in transduced HeLa cells: RT-PCR. Total RNA was extracted from HeLa cell clones transduced with pBabe-NRE (lane 1), pBabe-IRE (lane 3) and pBabe-REC (lane 5). RT-PCR was performed as described in Materials and methods. In lanes 2, 4, and 6 the RT-PCR was assembled in the absence of reverse transcriptase. The expected RT-PCR product (776 bp) is shown.
NRE was set to 100%. Compared with the control, luciferase activity was not significantly altered in HeLa cells transduced with pBabe-puro, whereas clones transduced with pBabe-IRE showed a modest reduction in luciferase activity, probably due to an antisense effect of the inactive ribozyme. In contrast, transduction of HeLa cells with pBabe-REC resulted in almost a complete reduction in luciferase activity. A remaining activity of only 3% was detected in six independently isolated clones. Expression of ribozymes in these clones was confirmed by RT-PCR (Figure 3b) . -ras-transformed cells transduced with pBabe-REC were no longer able to form factor-independent colonies and displayed a doseresponse to IL-3 stimulation which was almost identical Figure 6 ). Additionally, expression of pBabe-REC increased the percentage of cells which was positive by benzidine staining from 1% (without ribozyme) to 15% in response to Epo stimulation ( Figure 7) .
In order to analyze whether the reversal of the transformed phenotype was due to a reduction in the amounts of N 
Discussion
Owing to their high specificity and catalytic properties, ribozymes are excellent tools to control levels of gene expression. In particular, their intrinsic potential to reduce or abolish expression of oncogenes and their possible use as antiviral agents has motivated active research on their application as therapeutic agents. For most clinical settings, ribozymes will have to be constantly expressed inside the cell to ensure high levels of catalytic RNA. For this, retroviruses are particularly useful since they are simple in structure, easy to generate, and induce high levels of expression in infected cells.
Previously, we described the specificity and efficiency of a synthetic hammerhead ribozyme targeted against an oncogenic form of N-Ras. This ribozyme, MRE763C, was found to be specific for N-ras transcripts containing a 
-ras were transduced with pBabe-puro (#5/1 and #5/2), the active ribozyme, pBabe-REC (#5/1+REC and #5/2+REC), or a nonsense ribozyme, pBabe-NRE (#5/1+NRE and #5/2+NRE) and compared in their Epo-induced proliferation with control TF-1 cells transduced with MSCVneoEB. Cells were plated at 10 4 cells/ml in triplicate wells with different concentrations of Epo and counted after 7 days. The mean values were calculated from six independent experiments.
Figure 7 Expression of the active ribozyme, pBabe-REC, partially restores Epo induced differentiation. N 13 -ras clones 5/1 and 5/2 were transduced with the retroviral vector alone (pBabe-puro, grey bars), the active ribozyme (pBabe-REC, black bars) or a nonsense ribozyme (pBabe-NRE, white bars) and compared with control TF-1 cells (hatched bars). Cells were plated at 10
4 cells/ml in triplicate wells with 6 U/ml Epo and stained with benzidine after 7 days. point mutation at position 763 (G to C), as no cleavage of wild-type N-ras transcripts were observed in vitro and in cell lines. 20 In this study, we have analyzed the properties of MRE763C embedded within the body of the retroviral vector pBabe-REC, where expression from the viral 5Ј-LTR generates a transcript of 2658 nucleotides. When the retroviral ribozyme was tested in vitro using N 13 -ras transcripts as substrate, the catalytic properties were not severely reduced compared with a ribozyme transcript con- taining only 54 nucleotide flanking sequences. Similar observations have been made before, 26, 27 indicating that additional sequences on both sides of the ribozyme do not alter the catalytic properties of the ribozyme to a great extent, at least in vitro.
The pBabe-REC ribozyme was also analyzed in a HeLa cell clone expressing an N 13 -ras/luciferase fusion transcript. We have previously shown, that in this system a reduction of luciferase activity is accompanied by a reduction in the levels of N 13 /luciferase mRNA. 20 Exogenous delivery of the synthetic MRE763C ribozyme led to a 55% decrease in luciferase activity. In this study, by transducing the HeLa cells with the retroviral vector, pBabe-REC, we are able to show a much greater reduction in luciferase activity (97%). A direct comparison between these two sets of experiments is difficult since pBabe-REC-transduced cells were selected for ribozyme expression while, in the case of exogenous delivery, no selective pressure for the uptake of the ribozyme was applied. However, the antisense effect observed in MRE763C-or pBabe-IRE-treated cells was the same (approximately 20%), suggesting that the higher reduction in luciferase activity observed in cells transduced with pBabe-REC was due to: (1) higher expression levels of the ribozyme; (2) increased stability of the 2658 nucleotides long ribozyme; or (3) better accessibility of the ribozyme to the substrate, for example, through colocalization, or a combination of these factors.
Additionally, pBabe-REC is able to revert the transformed phenotype in N
13
-ras expressing TF-1 cells. TF-1 cells were originally isolated from a patient with erythroleukemia, but in culture they have retained certain properties associated with multipotential stem cells. They express the surface marker CD34 and require IL-3 for growth. Additionally, they can be induced to undergo growth arrest and differentiation into the erythroid lineage after stimulation with Epo. 25 Expression of an oncogenic form of N-ras in this cell line leads to factor-independent growth and proliferation in response to Epo stimulation. 9 The growth pattern seen in N
-ras-transformed TF-1 resembles the transition from a preleukemic phenotype to a full blown leukemic phenotype, which is characterized by a differentiation block and unrestricted growth. After infection of N
-ras-transformed TF-1 cells with pBabe-REC, cells were no longer able to form factorindependent colonies and displayed a dose-response to IL-3 stimulation, which was almost identical to wild-type TF-1 cells. This effect was specific, since the transformed phenotype was not reverted by infection with a retrovirus containing a nonsense ribozyme (pBabe-NRE) or the vector alone (pBabe-puro). Similarly, the proliferative response to Epo was abrogated, while the block in differentiation was only partially released. Similar results have been obtained with retroviral vectors containing ribozymes directed against oncogenic H-ras in the human malignant melanoma cell line FEM. 28 The differential effect of the ribozyme in cell proliferation and differentiation could be related to the fact that low concentrations of oncogenic Ras are required to interfere with differentiation, whereas high amounts of N 13 -ras are needed for a fully transformed phenotype. 29 In accordance with these observations, Northern blot analysis showed a 10-fold reduction in the amount of N
-ras RNA in cells infected with pBabe-REC, indicating that the ribozyme treatment was effective but did not completely eliminate N 13 -ras transcripts. Taking into consideration that the amounts of oncogenic Ras required to transform cells in vitro exceeds the number of oncogenic Ras RNA molecules found in primary tumors by over 100-fold, 29 the experiments described here may provide a basis for the therapeutical application of pBabe-REC in N
-rastransformed cells.
Materials and methods
Ribozymes
The ribozymes MRE763C, iMRE763C and nMRE763C have been described previously. 20 Briefly, ribozyme MRE763C was designed to cleave N-ras transcipts containing a G to C transversion at position 763. Ribozyme iMRE763C is identical to MRE763C except for an adenine to guanine base change at position 5. Thus, iMRE763C binds but does not cleave N 13 -ras transcripts. A further control ribozyme was synthesized containing the catalytic site of MRE763C but no further homology to N 13 -ras sequences (nMRE763C).
Retroviral vectors
Oligonucleotides coding for MRE763C, iMRE763C and nMRE763C were synthesized in an Applied Biosystems (Weiterstadt, Germany) 380B DNA Synthesizer and cloned between the BamHI and EcoRI restriction sites of plasmid pBluescript (Stratagene, Heidelberg, Germany) to generate pBlue-REC, pBlue-IRE and pBlue-NRE, respectively. The correct structure of these plasmids was confirmed by DNA sequence analysis employing standard procedures. A 70 bp DNA fragment containing the different ribozymes was SalI-BamHI digested from pBlue-REC, pBlue-IRE and pBlue-NRE, and cloned in the multiple cloning site of the retroviral vector pBabe-puro 22 to generate the retroviral vectors pBabe-REC (active ribozyme MRE763C), pBabe-IRE (inactive version of ribozyme MRE763C) and pBabe-NRE (nonsense ribozyme).
The retroviral vector MSCVneoEB 24 was used to generate a retroviral vector containing a mutant N 13 -ras sequence. For this, the plasmid pMS5A-NRAS 20 was digested with ApaI and NotI and the resulting DNA fragment (900 bp) was cloned within the polylinker region of MSCVneoEB to generate MSCV-NRAS.
In vitro transcription and cleavage kinetics of MRE763C with synthetic substrates The cleavage kinetics of the retrovirally encoded ribozyme MRE763C were analyzed in vitro by using a 32 P-labeled N 13 -ras transcript as substrate. For this, plasmid pMS5B-NRAS, which contains N 13 -ras, was linearized with EcoRI and transcribed in vitro. Transcripts containing the ribozyme MRE763C were generated as follows: the retroviral vector pBabe-REC was digested with SacI and the 2590 bp DNA fragment cloned into pBluescript to generate pBlue-BabeREC. In vitro transcription of NotI digested pBlue-BebeREC was performed as described previously. 20 Similarly, an 86 nucleotides transcript containing MRE763C was generated from an EcoRI-digested pBlue-REC plasmid.
The cleavage reactions were performed under singleturnover conditions by mixing the RNA substrates and the ribozymes at different concentrations in 50 mm TrisHCl, pH 7.5, and 10 mm MgCl 2 . After incubation at 37°C for 1 h, the reaction was stopped by addition of 8 l loading buffer to each reaction tube. The cleavage products were analyzed on 6% denaturing polyacrylamid gels and scanned on a Molecular Dynamics (Sunnyvale, CA, USA) PhosphorImager. The single turnover values were determined as described previously. 23 Cell culture TF-1 cells were maintained in Iscove's modified Eagle's medium (IMDM) supplemented with 10% heat-inactivated FCS and 10 ng/ml IL-3. 25 For differentiation, TF-1 cells were plated in triplicate wells into 24-well dishes at 10 4 cells/ml in the absence or presence of different concentrations of erythropoietin (Boehringer Mannheim, Mannheim, Germany). After 7 days, cells were counted and stained. For colony growth, TF-1 cells were plated in triplicate 35-mm tissue culture plates at 10 3 cells/ml 1.125% methylcellulose containing 30% FCS, 2 mm glutamine, and ␤-mercaptoethanol. The cells were incubated for 10 days at different concentrations of IL-3 and colonies were counted under an inverted microscope.
Retroviral transduction
The retroviral constructs pBabe-REC, pBabe-IRE, pBabe-NRE and pBabe-puro (10 g each) were transfected into the GP + envAM12 retrovirus packaging cell line 30 by calcium phosphate precipitation. 31 Puromycin-resistant clones were obtained after 14 days selection in medium containing 1.5 g/ml puromycin. Individual clones were isolated, expanded and screened for high-titer production by infection of NIH 3T3 with serial dilutions of the viral supernatants.
HeLa cells were infected with virus supernatants (titers: 5-6 × 10 5 ) containing the various ribozyme constructs in the presence of 8 g/ml polybrene. After 48 h the cells were cultured with selective medium containing 1.5 g/ml puromycin for 14 days. Six resistant puromycin-resistant colonies for each construct were isolated.
1233
TF-1 cells were infected with the ribozyme constructs in the presence of protamine sulfate (4 g/ml) and IL-3 (20 ng/ml). Infections proceeded by spinning the cells (2500 r.p.m.) with virus supernatant for 90 min at 32°C followed by a 2.5 h incubation at 37°C before removing the retroviral supernatant. After 48 h cells were selected in medium containing 1.5 g/ml puromycin for 14-16 days. The resulting pools of G418-resistant cells were used for functional analysis.
TF-1 cells transduced with MSCVneoEB and MSCV-NRAS were generated by incubating cells with transiently prepared retroviral supernatants. For this, Pheonix-A packaging cells (kindly provided by G Nolan, Stanford University, Stanford, USA) were transfected with MSCVneoEB or MSCV-NRAS DNA (10 g). Retroviral supernatants were collected 48 h later, filtered, and used to transduced TF-1 cells. Transfection efficiency in Pheonix cells was controlled by cotransfecting a RSVLacZ construct (10 g). Colonies of transduced TF-1 cells were selected in methylcellulose in the presence of 800 g/ml active G418 and 20 ng/ml IL-3. G418-resistant colonies were isolated after 12-14 days, expanded and tested for colony growth and differentiation.
Benzidine staining After 7 days of stimulation with erythropoietin, TF-1 cells were counted and stained as described previously. 32 A 5 l cell suspension was resuspended in 55 l IMDM, 10 l benzidine dihydrochloride (0.2%; Sigma, St Louis, MO, USA) and 1 l H 2 O 2 (30%). The percentage of bluestained cells was assessed with an hematocytometer after 5 min incubation at room temperature.
Luciferase assay
HeLa cells, expressing an N
13
-ras-luciferase fusion gene 20 were cultured in DMEM with 10% heat-inactivated fetal calf serum (Life Technology, Grand Island, NY, USA). Luciferase activity was determined by the Triton X-100 lysis method. 33 Protein concentrations determined with the Bradford protein assay were used to standardize the luciferase activity. 34 RT-PCR Total RNA from ribozyme-transduced cell lines was extracted by the guanidine thiocyanate-phenol chloroform extraction method. 35 Subsequently, the RNA samples were treated with RNase-free DNaseI (Boehringer Mannheim) for 1 h at 37°C, followed by phenol chloroform extraction and ethanol precipitation. Reverse transcription was performed according to the manufacturer's instructions (Promega). Five microliters of the RT reaction were amplified under standard PerkinElmer Cetus (Emeryville, CA, USA) PCR conditions (1 min at 94°C, 1 min at 60°C, and 2 min at 72°C for 25 cycles) in a final volume of 50 l with the following primers: RP-RE, 5Ј-AATTCAGCAGGTTTCGCTAACGCT CATCAGGTGTTGGG-3Ј and FP-RE, 5Ј-CTCTGT ATCTGGCGGACCCGTGGTGGAAC-3Ј. The resulting products (776 bp long) were analyzed on a 1.3% agarose gel.
Isolation of poly(A)+ RNA and Northern blot Poly(A)+ RNA was isolated as described previously. 36 In brief, 5 × 10 7 cells were washed twice with phosphatebuffered saline (PBS) and lysed in 10 ml of 0.5 m NaCl, 10 mm Tris pH 7.2, 10 mm EDTA, 0.3 mg/ml proteinase K and 1% SDS. To shear DNA, the cell lysate was passed once through a 22-gauge needle and four times through a 25-gauge needle. After incubation at 37°C for 3 h, the lysate was resuspended with 50 mg oligo(dT) cellulose (New England Biolab, Beverly, MA, USA) and rotated at 20°C for 18 h. The oligo (dT) cellulose was washed three times with 50 ml OBB (0.5 m NaCl, 10 mm Tris pH 7.2, 0.1 mm EDTA, 0.2% SDS), resuspended in 10 ml OBB, placed in a 10 ml polypropylene column (Bio-Rad, Hercules, CA, USA) and washed three more times with wash buffer (0.1 m NaCl, 10 mm Tris pH 7.2, 0.1 mm EDTA, 0.2% SDS). Poly(A)+ RNA was eluted by addition of OEB (10 mm Tris pH 7.2, 0.1 mm EDTA, 0.2% SDS) and recovered by ethanol precipitation. Five micrograms of poly(A)+ RNA were electrophoresed on a 1% agarose gel containing 2.2 m formaldehyde and then transferred onto nitrocellulose. The filter was then hybridized with a 32 Plabeled DNA probe containing the entire N 13 -ras sequence or GAPDH, washed and autoradiographed. 37 
